Zepbound (tirzepatide) is the FDA-approved anti-obesity formulation of tirzepatide, the same dual GIP/GLP-1 receptor agonist found in Mounjaro. Approved in November 2023 specifically for chronic weight management, it is available in doses from 2.5mg to 15mg administered as a once-weekly injection. Zepbound holds the distinction of producing the highest average weight loss of any FDA-approved anti-obesity medication to date. The SURMOUNT clinical trial program established its efficacy across diverse patient populations, including those with and without type 2 diabetes.
Zepbound patients lost an average of 14.9% body weight in the STEP 1 clinical trial (NEJM, 2021). Results typically begin within 4-8 weeks of starting treatment. Weight Method offers Zepbound from $297/month with virtual consultations and licensed providers.
Key Fact
Zepbound (tirzepatide) demonstrated the highest weight loss efficacy of any FDA-approved anti-obesity medication: 22.5% average loss at 15mg over 72 weeks in SURMOUNT-1. Results exceeded semaglutide by approximately 7.6 percentage points.
Source: SURMOUNT-1 — Jastreboff et al., NEJM 2022
SURMOUNT-1 trial: tirzepatide 15mg produced 22.5% average weight loss over 72 weeks — the highest of any FDA-approved anti-obesity medication, with over one-third losing 25%+.
The SURMOUNT-1 trial — Zepbound's landmark study — demonstrated an average weight loss of 22.5% at the 15mg dose over 72 weeks in adults with obesity without diabetes. This exceeds the results of every other FDA-approved weight loss medication by a significant margin. SURMOUNT-2, conducted in patients with type 2 diabetes and obesity, showed 14.7% average weight loss, confirming efficacy even in metabolically complex patients. More than one-third of SURMOUNT-1 participants on the highest dose lost over 25% of their body weight. Weight Method provides tirzepatide with comprehensive clinical monitoring at $349/mo.
Early appetite changes within 2-4 weeks at 2.5mg. Significant weight loss by week 12 as dosing escalates, with steady decline through 72 weeks and beyond.
Early appetite suppression and changes in eating patterns typically begin within 2-4 weeks of starting Zepbound at 2.5mg. Significant, measurable weight loss becomes evident by week 12 as the dose escalates into the therapeutic range of 10-15mg. The SURMOUNT-1 data shows weight loss continuing steadily through 72 weeks, with the steepest decline occurring between months 3-12. Patients on the 15mg dose saw continued improvement even beyond 72 weeks, suggesting the full timeline to peak results may extend past 18 months. Weight Method tracks your progress at every stage with regular clinical assessments.
Expect 15-22% body weight loss over 72 weeks depending on dose achieved. At 15mg, average loss was 52 lbs from a 231 lb starting weight in SURMOUNT-1.
Based on SURMOUNT trial data, patients starting Zepbound can expect average weight loss of 15-22% of body weight over 72 weeks, with results varying by dose achieved and individual factors. At the 15mg dose, the average participant in SURMOUNT-1 lost approximately 52 pounds from a starting weight of 231 pounds. Results at lower doses (5mg, 10mg) are still substantial at roughly 15-20% body weight loss. As with all GLP-1 medications, combining Zepbound with regular exercise and improved nutrition amplifies results beyond medication alone. Your Weight Method provider sets personalized milestones and adjusts your plan based on real-world progress.
Broad efficacy across patient profiles. Partial GLP-1 responders often improve with dual GIP/GLP-1 activation. Early appetite suppression in weeks 2-6 predicts strong long-term outcomes.
Zepbound's dual-agonist mechanism appears to produce strong responses across a wide range of patient profiles, as demonstrated by the SURMOUNT program's diverse enrollment. Patients who have tried GLP-1-only medications with partial success often see improved results with tirzepatide's added GIP receptor activation. Higher baseline BMI patients achieve larger absolute weight losses, though percentage reductions remain consistent. Early dose tolerance and appetite suppression in weeks 2-6 correlate with strong long-term outcomes. Weight Method's clinical evaluation helps determine if Zepbound's profile matches your health history and weight loss goals.
Take our 2-minute quiz to see if you qualify for GLP-1 treatment.
Start QuizFree consultation. No commitment.